Provisions of an Oesophageal Cell Collection Device (OCCD) and service delivery to pathology lab, pathology service and pathology reporting to NHS Scotland
A Prior Information Notice
by THE COMMON SERVICES AGENCY (MORE COMMONLY KNOWN AS NHS NATIONAL SERVICES SCOTLAND) (NSS)
- Source
- Find a Tender
- Type
- Future Contract (Services)
- Duration
- not specified
- Value
- 700K
- Sector
- HEALTH
- Published
- 07 Feb 2024
- Delivery
- not specified
- Deadline
- n/a
Concepts
Location
Any or all locations of NHS Scotland
1 buyer
- NHS National Services Scotland NSS Edinburgh
Description
This requirement is for an Oesophageal Cell Collection Device (OCCD) diagnostic service inclusive of delivery of pathology lab test to initiating clinician, which must be able to be integrated into the NHS, across Scotland with the aim of improving the patient journey, improving outcomes and reducing the requirement for traditional hospital-based procedures. As outlined above, Supplier must be able to provide holistic service of an Oesophageal Cell Collection Device (OCCD) and diagnostic service inclusive of delivery of pathology lab test.
CPV Codes
- 85111800 - Pathology services
Indicators
Other Information
Following a review of Upper GI endoscopy diagnostic testing, it was identified there is a requirement for a minimally invasive diagnostic test, without the use of sedation in patients who require screening or surveillance of Oesophageal pathologies such as Barrett’s Oesophagus (BE known pre-malignant lesion for oesophageal adenocarcinoma). Patients with reflux predominant upper GI symptoms who have been referred for urgent Upper GI endoscopy with concern of pre or early oesophageal cancer and/or patient’s with known Barrett’s oesophagus who are at risk of oesophageal cancer with progressive symptoms and/or who have had significant delay in their upper GI endoscopy would be eligible for the diagnostic test. The Pathology laboratory test should include –TFF3 (Trefoil Factor 3) biomarker (BE specific marker), and p53 and atypia reporting to define high-risk criteria. NHS Scotland has made the decision to implement a national approach for the Provision of an Oesophageal Cell Collection Device (OCCD) and service delivery to pathology lab, pathology service and pathology reporting, in a 'Once for Scotland' approach. This procurement is to identify a holistic service provider that will be implemented across all NHS Scotland health boards for this provision. NOTE: To register your interest in this notice and obtain any additional information please visit the Public Contracts Scotland Web Site at https://www.publiccontractsscotland.gov.uk/Search/Search_Switch.aspx?ID=757026. (SC Ref:757026)
Reference
- FTS 004041-2024